Artelo Biosciences (ARTL) Stock Statistics & Valuation Metrics

Artelo Biosciences has a market cap or net worth of $2.66M. The enterprise value is $8.08M.

Artelo Biosciences has 708,258 shares outstanding. The number of shares has decreased by -2.65% in one year.

Artelo Biosciences’s return on equity (ROE) is 10.13 and return on invested capital (ROIC) is 1969.60%.

The current PE Ratio of Artelo Biosciences is ―. Artelo Biosciences’s PEG ratio is -0.00051.

In the last 12 months, Artelo Biosciences had revenue of 0.00 and earned -12.88M in profits. Earnings per share was -5.47.

In the last 12 months, operating cash flow was -9.86M and capital expenditures 0.00, giving a free cash flow of -9.86M billion.

Artelo Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Artelo Biosciences upcoming earnings date is Apr 1, 2026, TBA (Confirmed).

Artelo Biosciences as a current ratio of 0.17, with Debt / Equity ratio of -54.48%

In the past 12 months, Artelo Biosciences has paid 0.00 in taxes.

Artelo Biosciences EV to EBITDA ratio is -0.24, with an EV/FCF ratio of -0.35.

Artelo Biosciences has $600.00K in cash and marketable securities with $693.00K in debt, giving a net cash position of -$93.00K billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Artelo Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―